Literature DB >> 8393325

Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers.

J L Broers1, J Viallet, S M Jensen, H Pass, W D Travis, J D Minna, R I Linnoila.   

Abstract

We performed in situ hybridization for c-myc, N-myc, and L-myc mRNA expression using 35S-labeled cRNA probes on frozen sections of 19 pairs of non-small cell lung cancers (NSCLC) and the surrounding non-neoplastic lung tissue. In non-neoplastic lung, c-myc expression was strongest in bronchial epithelium basal cells and hyperplastic alveolar type II pneumocytes, which are potential progenitor cells for bronchopulmonary epithelium and their tumors. In contrast, N-myc and L-myc mRNAs were not detected in non-neoplastic lung. In studies of freshly resected primary tumors, expression of c-myc was detected in 11 of 19 NSCLC (with the highest levels in squamous cell carcinomas), two of which also expressed L-myc, while N-myc expression was never detected. Levels of c-myc expression in tumors were significantly higher than in non-neoplastic lung samples. We conclude that: (1) c-myc expression in non-neoplastic lung tissues is highest in bronchial basal cells and hyperplastic type II cells, and (2) in NSCLC, overexpression of the myc-proto-oncogene is common.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393325     DOI: 10.1165/ajrcmb/9.1.33

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  16 in total

1.  The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Authors:  R T Nitta; C A Del Vecchio; A H Chu; S S Mitra; A K Godwin; A J Wong
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

2.  CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence.

Authors:  Y-T Chou; C-H Hsieh; S-H Chiou; C-F Hsu; Y-R Kao; C-C Lee; C-H Chung; Y-H Wang; H-S Hsu; S-T Pang; Y-S Shieh; C-W Wu
Journal:  Cell Death Differ       Date:  2012-07-20       Impact factor: 15.828

3.  Inhibition of Anaplerotic Glutaminolysis Underlies Selenite Toxicity in Human Lung Cancer.

Authors:  Ronald C Bruntz; Alex C Belshoff; Yan Zhang; Jessica K A Macedo; Richard M Higashi; Andrew N Lane; Teresa W-M Fan
Journal:  Proteomics       Date:  2019-09-12       Impact factor: 3.984

4.  Global detection of molecular changes reveals concurrent alteration of several biological pathways in nonsmall cell lung cancer cells.

Authors:  Z Ju; M Kapoor; K Newton; K Cheon; A Ramaswamy; R Lotan; L C Strong; J S Koo
Journal:  Mol Genet Genomics       Date:  2005-10-11       Impact factor: 3.291

Review 5.  Molecular biology of lung cancer: clinical implications.

Authors:  Jill E Larsen; John D Minna
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

6.  Increased susceptibility to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in transgenic mice overexpressing c-myc and epidermal growth factor in alveolar type II cells.

Authors:  A Ehrhardt; T Bartels; R Klocke; D Paul; R Halter
Journal:  J Cancer Res Clin Oncol       Date:  2003-02-19       Impact factor: 4.553

7.  MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Authors:  Antonella Flacco; Vienna Ludovini; Fortunato Bianconi; Mark Ragusa; Guido Bellezza; Francesca R Tofanetti; Lorenza Pistola; Annamaria Siggillino; Jacopo Vannucci; Lucio Cagini; Angelo Sidoni; Francesco Puma; Marileila Varella-Garcia; Lucio Crinò
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

8.  Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.

Authors:  Katerina Vrzalikova; Joseph Skarda; Jiri Ehrmann; Paul G Murray; Eduard Fridman; Jury Kopolovic; Petra Knizetova; Marian Hajduch; Jiri Klein; Vitezslav Kolek; Lenka Radova; Zdenek Kolar
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-09       Impact factor: 4.553

9.  Design, synthesis and biological evaluation of a novel class of anticancer agents: anthracenylisoxazole lexitropsin conjugates.

Authors:  Xiaochun Han; Chun Li; Michael D Mosher; Kevin C Rider; Peiwen Zhou; Ronald L Crawford; William Fusco; Andrzej Paszczynski; Nicholas R Natale
Journal:  Bioorg Med Chem       Date:  2008-12-31       Impact factor: 3.641

10.  A mathematical model for microRNA in lung cancer.

Authors:  Hye-Won Kang; Melissa Crawford; Muller Fabbri; Gerard Nuovo; Michela Garofalo; S Patrick Nana-Sinkam; Avner Friedman
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.